



GOG PARTNERS CONNECTION

A Quarterly Newsletter

From GOG Partners, A GOG Foundation Program

The GOG Foundation, Inc. has one mission:
Transforming the standard of care in gynecologic oncology

INCLUSION, DIVERSITY, EQUITY, and ACCESS (IDEA) COMMITMENT

Collaborating to Raise Awareness, Educate, and Encourage
Participation of Underrepresented Patients in Clinical Trials

The GOG Foundation, Inc. (GOG-F) announced the launch of the IDEA Commitment Education Modules on Thursday, July 25, 2024 at the NRG Semi-Annual Meeting in Denver, Colorado.



These new education modules are available on the GOG website:

- Commitment to DEI
- Community Engagement
- Protocol Design
- Study Conduct Accountability
- Advocacy

[Click here](#) to view the education modules on the GOG IDEA Commitment website page

COMMITMENT TO DEI	COMMUNITY ENGAGEMENT	PROTOCOL DESIGN	STUDY CONDUCT ACCOUNTABILITY	ADVOCACY
<p>Tashanna Myers, MD Baystate Medical Center</p> <p>Tara Castellano, MD LSU Health Sciences Center</p> <p>Brian Slomovitz, MD Mount Sinai Medical Center Miami Beach</p>	<p>Bradley Monk, MD Florida Cancer Specialist and Research Institute</p> <p>Destin Black, MD Willis-Knighton Health System</p> <p>Joan Walker, MD University of Oklahoma Stephenson Cancer Center</p>	<p>Kathleen Moore, MD University of Oklahoma Stephenson Cancer Center</p> <p>Roisin O'Cearbhaill, MD Memorial Sloan Kettering Cancer Center</p> <p>Dana Chase, MD University of California Los Angeles</p>	<p>Robert Coleman, MD Texas Oncology Vanam Group</p> <p>Amanda Jackson, MD University of Cincinnati</p> <p>Victoria Bae-Jump, MD, PhD UNC Lineberger Comprehensive Cancer Center</p>	<p>Colleen McCormick, MD University of New Mexico</p> <p>Sharad Ghamande, MD Sharad Ghamande, MD</p> <p>Leslie Randall, MD Moore's Cancer Center Virginia Commonwealth University</p>

The GOG-F would like to thank our commercial partners for their support of the GOG's IDEA Commitment Initiative: *ImmunoGen* and *GSK*.

For more information on the GOG's IDEA Commitment Initiative, please visit our website at www.gog.org/idea-commitment to join us in making your IDEA Commitment!

SGO/GOG-F BRIDGES 2.0 RESEARCH INITIATIVE

With Support from the FWC



The Society of Gynecologic Oncology (SGO) and The GOG Foundation, Inc. (GOG-F) kicked off the BRIDGES 2.0 Research Initiative with support from the Foundation for Women's Cancer (FWC) on Saturday, July 27, 2024 in Denver, Colorado.



SGO President and BRIDGES 2.0 Co-Director Dr. Amanda Fader welcomed the new BRIDGES Scholars along with Co-Director Dr. Sarah Adams, GOG-F President Dr. Thomas Herzog, and SGO Immediate Past President Dr. Angeles Alvarez Secord.

The BRIDGES 2.0 program is designed to equip gynecologic oncologists, medical oncologists, and radiation oncologists in the early stages of their careers with the skills, knowledge, and networks necessary to excel in clinical trials research.

Scholars will have the opportunity to learn from leading experts in the field, engage in cutting-edge research, and collaborate with peers, mentors, translational scientists, statisticians, and industry partners who share your passion and vision. This program will challenge, inspire, and empower these Scholars to transform innovative ideas into impactful clinical trials that can change the lives of patients worldwide.

[Click here](#) to meet the BRIDGES 2.0 Scholars

Have questions?

Please reach out to education@sgo.org.

The SGO, GOG-F and FWC wish to thank their generous BRIDGES 2.0 Research Initiative partners:

Ovarian Cancer Research Alliance, AstraZeneca, GSK, Merck, and Seagen

SPECIAL RECOGNITION

Giants of Cancer Care® Announces the 12th Annual Class of Inductees

Gynecologic Oncology Inductee:

Carol A Aghajanian, MD, Memorial Sloan Kettering Cancer Center

Congratulations Dr. Carol Aghajanian for your remarkable achievements in Gynecologic Oncology research and clinical practice.



The Giants of Cancer Care program aims to honor and celebrate the accomplishments of leading researchers and educators whose discoveries have propelled the field and set the groundwork for future advancements. A selection committee of more than 115 esteemed oncologists choose honorees from a range of tumor types and specialized categories. The inductees have been selected by their peers for their remarkable achievements in oncology research and clinical practice.

[Click here](#) to read the full article.

The GOG Foundation, Leadership Award

Ronald D. Alvarez, BS, MD, MBA

Thank you Dr. Ronald Alvarez for your incredible leadership and the work you have done to help advance the next generation of clinical trialists. You have made a profound impact in mentoring our future leaders and we are grateful for all you do to help make a difference in gynecologic oncology.



The GOG Foundation, Inc. 2019 Scholars

Congratulations inaugural 2019 GOG Scholar Investigators!

Our graduating class of GOG Scholar Investigators led ground-breaking gynecologic oncology clinical trials, conducted high-quality translational research, and presented at international conferences. Collectively, they had 100 publications and obtained over sixteen million in grant funding in five years.

Several GOG Scholars served as the principal investigator (PI) or co-PI on registration trials leading to FDA-approved therapies for endometrial and cervical cancer. Way to go Scholars - leading the way to transform the standard of care and improve the lives of all our patients.



Rebecca Arend, MD
University of Alabama at Birmingham



Lillian Gien, MD
Sunnybrook University



Emma Barber, MD★
Northwestern University



Debra Richardson, MD
University of Oklahoma



Lisa Barroilhet, MD★
University of Wisconsin



Ritu Salani, MD
University of California, LA



Katherine Fuh, MD, PhD★
University of California, San Francisco



Shannon Westin, MD
MD Anderson



Stephanie Galliard, MD, PhD
Johns Hopkins



Dmitry Zamarin, MD, PhD★★
MSKCC / Mount Sinai

Star indicates NIH R01 Research & Development Grant Recipient

Welcome Kristin Miller to The GOG Foundation, Inc.

Medical Writer, Grant Strategy and Communications

Kristin Miller is a dual certified Family Nurse and Acute Care Pediatrics Nurse Practitioner. With a foundation in research, Kristin brings 15 years of clinical experience from Cincinnati Children's Hospital Medical Center, combined with industry based medical communications and education experience to The GOG Foundation, Inc. Kristin will be fulfilling the role of Medical Writer, Communications, and Grant Strategy. A passionate clinical trials advocate, Kristin knows #clinicaltrials cure cancer and is ecstatic to join The GOG Foundation, Inc team and partner with our world renowned experts and biopharmaceutical partners to continue to transform the standard of care in gynecologic oncology.



IN THE NEWS

ENGOT-cx11/GOG-3047/KEYNOTE A-18 Press Release

Merck to Present Survival Data and New Research on 10 Investigational or Approved Medicines at ESMO Congress 2024

September 4, 2024: RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data for four approved medicines and six pipeline candidates in more than 20 types of cancer will be presented at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain, from Sept. 13-17. Study findings from the Phase 3 KEYNOTE-522 trial (#LBA4) in high-risk early-stage triple-negative breast cancer (TNBC), the Phase 3 KEYNOTE-A18 trial (#7090) in high-risk locally advanced cervical cancer and the Phase 3 LEAP-012 trial (#LBA3) in unresectable, non-metastatic hepatocellular carcinoma, in collaboration with Eisai, have been selected for the ESMO Presidential Symposium Sessions. Data being shared at the Congress showcase the company's continued progress in advancing clinical research for Merck's broad portfolio and diverse pipeline of investigational candidates, with a total of 80 abstracts being presented.

[Click here](#) to view the full press release.

GOG-3031 RUBY FDA News Release

FDA expands endometrial cancer indication for dostarlimab-gxly with chemotherapy

On August 1, 2024, the Food and Drug Administration approved dostarlimab-gxly (Jemperli, GSK) with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for adult patients with primary advanced or recurrent endometrial cancer (EC). Dostarlimab-gxly previously was approved with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for primary advanced or recurrent EC that is mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H).

[Click here](#) to view the full news release.

ENGOT-EN6 | GOG-3031 RUBY Publication

Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin–paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial.

Volume 35, Issue 8, August 2024: Part 1 of the RUBY trial (NCT03981796) evaluated dostarlimab plus carboplatin–paclitaxel compared with placebo plus carboplatin–paclitaxel in patients with primary advanced or recurrent endometrial cancer (EC). At the first interim analysis, the trial met one of its dual primary endpoints with statistically significant progression-free survival benefits in the mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) and overall populations. Overall survival (OS) results are reported from the second interim analysis.

[Click here](#) to view the full publication.

innovaTV 301/ ENGOT cx-12/ GOG-3057 Publication

Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer

July 3, 2024: Background: Recurrent cervical cancer is a life-threatening disease, with limited treatment options available when disease progression occurs after first-line combination therapy.

Methods: We conducted a phase 3, multinational, open-label trial of tisotumab vedotin as second- or third-line therapy in patients with recurrent or metastatic cervical cancer. Patients were randomly assigned, in a 1:1 ratio, to receive tisotumab vedotin monotherapy (2.0 mg per kilogram of body weight every 3 weeks) or the investigator's choice of chemotherapy (topotecan, vinorelbine, gemcitabine, irinotecan, or pemetrexed). The primary end point was overall survival.

[Click here](#) to view the full publication.

KEYNOTE-868/ NRG-GY018 Press Release

FDA approves pembrolizumab with chemotherapy for primary advanced or recurrent endometrial carcinoma

On June 17, 2024, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult patients with primary advanced or recurrent endometrial carcinoma.

Full prescribing information for Keytruda will be posted on Drugs@FDA.

Efficacy was evaluated in KEYNOTE-868/NRG-GY018 (NCT03914612), a multicenter, randomized, double-blind, placebo-controlled trial enrolling 810 patients with advanced or recurrent endometrial carcinoma. The trial included two separate cohorts based on mismatch repair (MMR) status: 222 patients in the mismatch repair deficient (dMMR) cohort, and 588 patients in the mismatch repair (pMMR) proficient cohort. Patients were randomized (1:1) to one of the following treatment arms:

- pembrolizumab 200 mg every 3 weeks, paclitaxel 175 mg/m² and carboplatin AUC 5 mg/mL/min for 6 cycles, followed by pembrolizumab 400 mg every 6 weeks for up to 14 cycles.
- placebo every 3 weeks, paclitaxel 175 mg/m² and carboplatin AUC 5 mg/mL/min for 6 cycles, followed by placebo every 6 weeks for up to 14 cycles.

[Click here](#) to read the full press release.

CLINICAL TRIALS

The GOG Partners Program is currently recruiting for 22 clinical trials

- **11 Ovary**
- **3 Cervix**
- **8 Endometrium**



To search active trials visit our website by clicking Clinical Trials button below.

Clinical Trials

Top 50 Recruiting Sites GOG Partners/NRG Combined

GOG FOUNDATION[®]
Transforming the standard of care

TOP 50 RECRUITING SITES – 1 YEAR GOG Partners/NRG Combined Accrual

GOG PARTNERS

Combined Accrual: Institution

51	The Ohio State University Comprehensive Cancer Center
35	Women's Cancer Center of Nevada
33	University of Oklahoma Health Sciences Center
27	Memorial Sloan Kettering Cancer Center
25	NYU Langone Medical Center - NYU Clinical Cancer Center - Womens Cancer Program
24	University of Virginia
24	Froedtert and The Medical College of Wisconsin
23	HonorHealth Research and Innovation Institute - USO
23	Women & Infants Hospital

Combined Accrual: Institution

21	Center of Hope
19	Indiana University Melvin and Bren Simon Comprehensive Cancer Center
17	Texas Oncology - Fort Worth - USO
17	Washington University School of Medicine
17	Georgia Regents/Augusta University
16	Rutgers Cancer Institute of NJ
16	Northwestern University
15	Mount Sinai Medical Center
14	Minnesota Oncology Hematology, PA - Maplewood

NRG
ONCOLOGY
Advancing Research. Improving Lives.



SCAN ME

CONFIDENTIAL

07-01-2023 through 6-30-2024

GOG Partners/NRG Combined Accrual

Combined Accrual: Institution

14	University of Colorado Hospital - Anschutz Cancer Pavilion
13	Cleveland Clinic Foundation
12	Duke University Medical Center
12	Virginia Commonwealth University
12	New Mexico Cancer Care Alliance/ University of New Mexico Comprehensive Cancer Center
12	Levine Cancer Institute, Atrium Health (Carolinas Medical Center)
12	Baystate Medical Center
12	Huntsman Cancer Institute
11	University of California San Diego Moores Cancer Center

Combined Accrual: Institution

11	Dana Farber Cancer Institute
11	MD Anderson Cancer Center
11	University of Washington Fred Hutchinson Cancer Center (FHCC)/Seattle Cancer Care Alliance
11	University of Nebraska Medical Center
10	University of Pennsylvania
10	Avera Cancer Institute
10	SUNY Upstate Medical University
10	The Blavatnik Family - Chelsea Medical Center at Mount Sinai
9	Western Pennsylvania Hospital/ West Penn Hospital - Allegheny Health Network



SCAN ME

CONFIDENTIAL

07-01-2023 through 6-30-2024

GOG Partners/NRG Combined Accrual

Combined Accrual: Institution

9	Icahn School of Medicine at Mount Sinai
9	Abington Memorial Hospital - Asplundh Cancer Pavilion/Thomas Jefferson
9	University of Chicago Medical Center
9	University of Wisconsin
9	University of Iowa Hospitals and Clinics
9	Good Samaritan Hospital
9	Weill Cornell Medicine - New York Presbyterian Hospital
8	Texas Oncology - The Woodlands, Gynecologic Oncology - USO
8	Stanford University

Combined Accrual: Institution

8	HCA MidAmerica Division (previously Midwest Kansas City)
8	Trials365, LLC
8	Women's Cancer Care Associates, LLC
8	University of Arkansas for Medical Sciences
8	Swedish Medical Center
8	University of Alabama at Birmingham
8	Maine Medical Center
8	Mayo Clinic Rochester
8	University of Rochester



SCAN ME

CONFIDENTIAL

07-01-2023 through 6-30-2024

GOG-3047 KEYNOTE A18 & GOG-3057 innovaTV 301 CLINICAL TRIAL REVIEW



OnPrime GOG-3076 Enrollement Update

A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec followed by Platinum-doublet Chemotherapy and Bevacizumab Compared with Chemotherapy and Bevacizumab in Women with Platinum-Resistant/Refractory Ovarian Cancer

Reasons to Join This Pivotal Trial

- No cap on number of prior lines
- Both primary & secondary platinum-refractory diseases also allowed
- No limitation on BRCA, HR or MMR status
- No requirement for a specific tumor cell surface receptor or ligand
- Temporary catheter only in place for 1-2 weeks
- 2:1 chance of randomization into the Experimental (Olvi-Vec) Arm
- [Click here](#) for more information on this clinical trial.

Additional Resources

- [Click here](#) to view Dr. Erin Crane's GOG-3076 OnPrime Clinical Trial Update video.
- [Click here](#) to view Dr. Robert Holloway, Dr. Premal Thaker, and Dr. Alberto Mendivill's Trailblazing Treatments video.

Contact Katie Campbell at kcampbell@gog.org to learn more about this exciting opportunity to participate in the OnPrime/GOG-3076 Phase 3 trial in PRROC.

UPCOMING INDUSTRY MEETINGS

NRG Oncology 2025 Winter Semiannual Meeting

The NRG Winter 2025 Semiannual Meeting will be held in person at the Phoenix Convention Center in Phoenix, AZ, from **January 16, 2025 - January 18, 2025**.



NRG Oncology will offer a full program that includes scientific sessions, engaged educational session for early-career investigators, and opportunities for networking events. We are excited to offer an expanded Winter Symposium. Learn more about the full program on the Agenda & Session Information page (COMING SOON). Select sessions will be held virtually on January 13, 2025 - January 14, 2025, ahead of the meeting.

[Click here](#) for more information on the NRG Oncology 2025 Winter Meeting.

SGO 2025 Winter Meeting

The SGO 2025 Winter Meeting will be held at the Fairmont Chateau Whistler in Whistler, BC, Canada, from **January 30, 2025 - February 1, 2025**.



The SGO Winter Meeting fosters collaboration among researchers at all career stages through specialized scientific sessions, insightful posters, and intimate networking events. Attendees can also enjoy exciting winter and wellness activities, blending professional growth with a relaxing retreat. The meeting's close-knit atmosphere creates a unique environment for building connections with established leaders in gynecologic oncology.

[Click here](#) for more information on the SGO 2025 Winter Meeting!

ESGO 2025 Congress

The ESGO 2025 Congress will be held at the Centro Congressi Roma La Nuvola in Rome, Italy, from **February 20- 23, 2025**.



ESGO 2025 will be a celebration of discovery and late-breaking research, new guidelines, practical demonstrations, and exclusive live surgery transmissions you don't want to miss.

The 26th Congress of the European Society of Gynaecological Oncology will bring together over 2,500 attendees from around the world for gathering of learning, networking, and sharing the latest developments in the field of Gynaecological Cancers—all with the goal of enhancing your knowledge, accelerating your skills and advancing the field.

[Click here](#) for more information on the ESGO 2025 Congress!

ON DEMAND EDUCATION

The GOG Highlight Reel - July 2024

The GOG Highlight Reel condenses 12 days of meetings into two and a half hours, distilling practice-changing data from major medical meetings. This comprehensive course takes a deep dive into clinical trials for gynecologic malignancies, offering insights on recent data presentations, ongoing research, and competitive dynamics shaping the field. It addresses common gynecologic malignancies, aiding physicians in navigating the evolving landscape. Participants not only receive a synthesis of recent studies but also explore key components of clinical trials, gaining essential knowledge for research in these malignancies. Dynamic discussions analyze emerging therapies and investigational agents, providing insights into current trends and advancements. Join us for a journey through clinical trials in ovarian and endometrial cancers, gaining the skills to navigate oncology research confidently.



[Click here](#) to access the recording.



GOG Foundation Inc. | Four Penn Center 1600 JFK Blvd. Suite 1020 | Philadelphia, PA
19103 US

[Unsubscribe](#) | [Update Profile](#) | [Constant Contact Data Notice](#)



Try email marketing for free today!